TrialBritish journal of cancer2013

Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO study.

C de la Piedra et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.